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y Friends and Colleagues, Welcome to
Austin! It has been the honor of my
lifetime to serve as your president. The
relationships forged in this most amazing of
professions, especially at gatherings like these, are
what I value the most—which is why I feel
blessed that we are here in person to share our
innovations for the future. Of course, when we ﬁrst
conceived of the theme for this meeting a few years
ago, it was a play on the upcoming year 2020 when
we expected to be together in Miami, hoping to
share our own “20/20 Vision for the Future.”
Well, history taught us that “vision” is not a
crystal ball. Although no one could have predicted
these unprecedented times, I am not surprised that
neurosurgery has found a silver lining through this
pandemic to come together in the service of our
patients and our profession, to move our frontiers
ever forward. Today, as we reimagine our own
vision for the future, please join me on a journey
through time as we reﬂect on where we have been,
in each of our subspecialties, and how far we have
come. Just a few short years ago, the tools and
techniques used today in our operating rooms,
clinics, and laboratories would have seemed like
far-off space age science ﬁction, yet collectively we
made it a reality.
Are we adequately preparing the next generation of neurosurgeons, for what comes next?
Together, we need to enhance our educational
platform and expand the reach of our profession
so that neurosurgery remains at the tip of the
spear. Our colleagues desire it. Our trainees need
it. Our patients deserve no less.
Before I begin, I must thank my own department, without whose support and camaraderie it would have been impossible to make it
through not only this year but also for the past
17 years I have called Henry Ford home. Thank
you to Jack Rock for being an amazing interim
chair after I took on the chief executive ofﬁcer
(CEO) role, and to Ghaus Malik, Mike Chedid,
Mwafa Abdulhak, Ellen Air, Jason Schwalb, Ian
Lee, Adam Robin, Asim Mahmood, Don Seyfried, Vic Chang, Max Kole, Tom Mikkelsen,
Tobias Walbert, and so many others, for your
friendship and mentorship.

To my Congress of Neurological Surgeons
(CNS) family—starting with the legacy of passionate volunteers who ﬁrst gathered in 1951, to
my own Executive Committee—our journey over
the past 12 years when Elad Levy and I ﬁrst came
on the executive committee together until now has
been one of my career’s prized experiences… and it
is all made possible by the most dedicated staff in all
of organized medicine, led by the truly exceptional
Regina Shupak and also Deanne Starr, April
Martin, David Berg, and their incredible teams.
I am so honored to have called Brian Hoh a
close friend ever since we were in residency together 2 decades ago, and he has been a phenomenal leader for this organization.
This year represents a combined extravaganza
of the best highlights from our planned 2020
meeting and our 2021 lineup, thanks to the
herculean efforts of Nader Pouratian, our scientiﬁc program virtuosos Brian Nahed, Ashok
Asthagiri, and Lola Chambless—these are impossible jobs in any year—but imagine having to
plan, put on hold, cancel, reschedule, replan, and
get everything perfect along the way!
The time-honored tradition of selecting luminaries in our ﬁeld to serve as honored guests is alive
and well. Thank you to 2 of my most incredible
mentors who so signiﬁcantly shaped my own career: Bob Carter, my chief resident when I started at
Harvard-Massachusetts General Hospital and now
the Chair there, Mark Rosenblum, who recruited
me to Henry Ford and is now the Chair Emeritus,
and of course Brian’s 2021 Honored Guest, Bill
Friedman, the chair emeritus at the University of
Florida.
While it is impossible to thank everyone who
has inﬂuenced my professional journey, there are
several individuals in addition to those I have already mentioned who have made all the difference,
and I am forever grateful for your mentorship and
your friendship over many years. Neurosurgery is a
sport of lifelong learning, and I am so blessed to
have learned from all of you.
I took over my role as CEO at Henry Ford just
10 days before the pandemic struck Detroit,
which I assure you was not in the ﬁne print of the
contract…
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But no matter how dark the days became, we learned that in the
middle of difﬁculty lies opportunity, and hope, and that the heroes
of health care, and our patients, revealed many silver linings.
Including being able to launch a record number of new educational programs that brought our members together, even as
we remained apart—such as the CNS Townhall Experience,
Virtual Visiting Professor programs, Virtual Tumor Boards, and
the new Future Women Leaders in Neurosurgery Scholarship.
Our journals processed a record number of submissions (including 200 related to COVID) and launched our newest
publication, Neurosurgery Open.
Now, with this in-person meeting, as we gather as a neurosurgery family from across the globe, it is hoped that we can return
to our regularly scheduled program—innovating for the future.
When we think about innovation, we often think of Steve Jobs
and the modern digital revolution…but there are many lessons to
be learned from our own rich history in neurosurgery. In footage
from 100 years ago, Harvey Cushing can be seen laying the
groundwork for the future. In his day, 65% of patients died after
surgery. Through his meticulous techniques and discoveries,
mortality plummeted to 11% by the end of his career, allowing
neurosurgery to go beyond just palliative decompression to more
deﬁnitive surgery. Today, with surgical case mortality rates near
zero, our patients can expect a personalized, targeted approach to
care through the wonders of precision medicine, 3-dimensional
(3D) imaging, and navigation guidance. By examining how we
got here, we can better prepare for a future that is happening now.
Indeed, the possibilities are endless…
Let us examine each of our specialties to see how far we have
come and what we need to ensure future advances.
Beginning with my own ﬁeld of tumors, we learned yesterday
from Dr Rosenblum that electricity was believed to cure disease
and that applying current might dissolve tumors.
The ﬁrst operations for malignant glioma occurred in the
1880s, but all the patients at that time died of complications from
the surgery and not the disease itself.
As recently as the 1960s, this Elsberg cannula was used to probe
the brain blindly to allow the surgeon to “feel” where a more rigid
tumor might be located—which gives a whole new perspective to
the term “navigation probe.”
Today, of course, we have rocketed light-years ahead. We have
the luxury of real-time imaging with ﬁber tracking and functional
navigation to ensure safe and effective outcomes, allowing neurosurgeons access to parts of the brain previously deemed
inoperable.
The future of brain tumor therapy will be driven by nextgeneration navigation, minimally invasive and targeted techniques, and molecular innovations like liquid biopsy.
Four years ago, I was honored to accompany Dr Hadjipanayis
and a great team to secure Food and Drug Administration approval for 5-aminolevulinic acid (5-ALA), an oral prodrug that
takes advantage of the protoporphyrin-9 synthesis pathways to
form ﬂuorescent molecules, which selectively accumulate in tumor cells and not normal brain.
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The views from our ﬁrst case amazingly matched almost exactly
an artist’s stylized rendering.
After excitation with blue light, the tumor cells emit a red-violet
color, enabling surgeons to visualize tumor remnants that might
otherwise be left behind, allowing for a more complete resection
and thereby enhanced survival. Today, 5-ALA and intraoperative
MRI are just 2 of several intraoperative techniques pushing our
frontiers forward.
Raman spectroscopy, ﬁrst developed 100 years ago, was mainly
used in wartime battleﬁelds by the military to detect radiation
matter emitted by improvised explosive devices. Neurosurgeons
adapted this technology to human tissue after discovering that
Raman could detect brain tumor cells with 99% sensitivity.
We used a 1000 samples from our Henry Ford tissue bank to
develop a machine learning paradigm capable of distinguishing
normal vs glioma vs necrotic tissue within a fraction of a second,
linking it to a standard navigation probe, and a robotic arm, to
help make real-time resection decisions during surgery.
In the future, we might eliminate the half hour or more that we
spend waiting for frozen section results, with near-instant results
instead, including insight into molecular biomarkers like IDH1 in
real time.
In thinking about the next frontier of liquid biopsy, the author
Steven Johnson writes about innovation in his book, “Where good
ideas come from,” that massive breakthroughs do not just happen
in 1 step. Rather, you need to go through several doors like interconnected rooms in a house to reach your destination. So, from
Cushing to the Elsburg cannula, to early navigation efforts to 5ALA and Raman, the future of molecular genetic wonders is now
on us.
We all know what a glioblastoma multiforme looks like, but
imaging has its limitations. Right now, obtaining an actual tissue
diagnosis is still the standard of care. But what if all you needed
was an $8 blood test to detect circulating biomarkers within
minutes? In our laboratory, we compared 15 molecular markers
between matched blood and tissue samples and found that the
blood analysis predicted the correct tissue diagnosis with 100%
accuracy. In tumor boards of the future, we may soon have a
quick, accurate way of distinguishing true vs pseudotumor progression, with the hope of dramatically changing the trajectory of
this dreaded disease.
But how do we get there? By prioritizing innovation. Like many
institutions around the world, we are using thousands of clinically
annotated and serum-matched tissue samples to create animal
model avatars of our actual patients, in real time, to determine
which targeted therapies can best help a particular patient. We
then link these results with others globally to learn from, and
contribute to, real-world evidence. Our patients deserve no less,
and slowly but surely the frontiers are being moved.
To be more relevant for our patients, precision medicine innovations will need to be greatly reﬁned. We know that the
historical way of naming tumors based on their cell of origin no
longer tells the full story. We also know that distinguishing tumors by key molecular markers, such as isocitrate dehydrogenase
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(IDH) wild type, which confers a poor prognosis, can signal the
need for more advanced therapy. In the future, pharmacogenomics
can analyze these markers in the clinic to stratify a seemingly
homogeneous group of patients into different treatment groups,
with the goal of personalizing precision immunotherapy for
the best results. That is the lofty goal of many real-world
evidence trials—so that the experience of a patient in Tokyo or
London can be relevant in real time for a patient with a similar
proﬁle in Detroit or San Diego, and in the days before science
became so politicized, many of our leaders with a personal
experience with brain tumors encouraged exactly this type of
innovation.
So what is next? The global bioinformatic crowdsourcing of
massive data might identify—and cure—patients before they even
develop a disease—a so-called previvor, or a survivor of a
predisposition…
But we know that our journey has only just begun. Today, we
have many tools at our disposal, like evidence-based guidelines
that seek to ensure a high standard of care, literally at the ﬁngertips
now of every neurosurgeon in the world. The history of neurosurgical innovation guides each of our subspecialties.
For vascular neurosurgery and stroke in particular, tissue
plasminogen activator (tPA) was developed in the 1970s and used
widely for treatment in the mid-1990s, but the revolution continued with the advent of thrombectomy. Recent stroke trials
made the impossible possible by extending the window that
patients could be treated for potentially devastating strokes, from
3 to 24 hours. The synergistic interplay between endovascular
device design and real-time imaging allows clots deep within the
brain to be removed, and function restored.
The progress in open vascular surgery has been equally stunning. From the early preoperative planning sketches by William
Osler a century ago to today’s instant, preoperative 3D imaging
guidance, vascular surgery is safer and better controlled, and even
when ruptures occur, 3D imaging guidance and pre-op anatomic
planning software prepare the surgeon to handle almost any
eventuality.
After we almost lost the ability to perform instrumentation in
the 1990s, spine is now rightfully a neurosurgical endeavor, with
better and better quality safeguards. Cushing himself performed
the ﬁrst intraspinal tumor surgery in 1900, and in the decades that
followed, advanced wiring and screw ﬁxation systems were developed. Some innovations, such as the anterior cervical plating
construct developed almost 60 years ago, are still used with great
success today: from early ﬁxation devices to the modern era,
including minimally invasive techniques and advanced real-time
imaging navigation. Preplanning software now allows surgeons to
perform, based on real anatomic landmarks, the most complex
spinal reconstructions in a safe, robotically assisted manner, with
impressive outcomes.
To address concerns of value, appropriateness of surgery, and
outcomes, we have looked to data to secure our future. One
example is the Michigan Spine Surgery Improvement Collaborative analyzing 71 000 detailed patient journeys from more than
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30 hospitals, as a statewide platform to improve outcomes. By
promoting transparency and sharing best practices, this initiative
has already resulted in decreased infections, cost, and post-op
complications, while also improving return to work rates and
other outcomes. We must invest in similar efforts globally.
Innovation has also helped our youngest and most vulnerable
patients. We have come a long way from the need for multiple,
repeated shunt surgeries to now the routine use of endoscopic
surgeries for pediatric hydrocephalus, and many other conditions.
In epilepsy, traditional grids and strips paved the way for
precision robotics and the use of 3D printing and minimally
invasive repair at very early ages have revolutionized the treatment
and outcomes for complex craniofacial congenital anomalies.
Our commitment to innovation has led to countless more
patients surviving and even thriving, after catastrophic traumatic
injury, from the earliest known trephination of skulls in prehistoric times to the ﬁrst craniotomies performed for trauma by
Cushing for wounded soldiers in World War 1. The 20th century
brought intracranial pressure monitoring, mechanical ventilation,
America’s 911 system, and the Glasgow Coma Scale. From the
ﬁrst computed tomography scan in 1972 to more than 30 000
available in almost every corner of the world today, the mantra of
“time is brain” has led to novel therapies and better outcomes,
from the earliest images unlocking the secrets of the brain to
modern precision images available on portable scanners within
seconds.
It is incumbent on us to develop more powerful treatments for
devastating strokes and neural injury…Exosomes, the “Fed Ex”
delivery agents for precise genetic instructions to cells, hold great
promise. In the near future—even for human beings, the most
genetically diverse organisms—we should be able to unlock the
secrets of this exosome-mediated “master switch,” of microribonucleic acid transport of key proteins, to restore brain and
spinal cord function. But we must invest now in that future.
Finally, the wonders of functional neurosurgery are boundless,
from Victor Horsley’s ﬁrst ablation of the motor cortex for
movement disorders in the 1890s to the development of the
stereotactic frame. The innovation of 3D grids addressed the
challenge of 70% of the cortex being located in sulcal folds. With
robotic electrode placement, all-day cases can now be performed
in an hour. In thinking about depression, our pioneering colleagues have even adapted the learnings from epilepsy monitoring
to a new approach for deep brain stimulation for depression,
which afﬂicts millions of people worldwide. At the same time,
traditional deep brain stimulation leads are implanted, so are
monitoring leads, which can elucidate how brain networks are
altered in depression and which parameters can best help individual patients. A monkey playing MindPong without a joystick
shows an amazing concept of decoding patterns of neural activity
used in every day movement. Soon, paralyzed patients might
recreate the same functions with their mind, not their muscles,
through a greater understanding of neural networks.
There is perhaps no greater imperative for visioning the future
than helping blind people see. With new visual cortical implants,
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the future is, quite literally, very bright. Here, cortical implants
allow a blind man to correctly identify colored shapes with 100%
accuracy. In the future, artiﬁcial intelligence and virtual reality will
push the envelope even further. In 1 example from Dr Pouratian’s
team, 1 man never dreamed that he would see light or movement
again, after losing his sight in a car accident, but with the ﬂick of a
switch, his world suddenly grew. A groundbreaking implant
converts images from a tiny video camera on a pair of sunglasses
into a series of electrical pulses that the brain perceives as visual
cues. These ﬂickers of light can signal where a sidewalk begins or
ends, or when a person enters a room, enhancing functional
independence with daily tasks such as sorting laundry by distinguishing light from dark and safely crossing a street. The future
is now.
But so is our imperative to invest in and nurture that future
vision. With this tour de force of our collective history, I hope that
I have convinced you that innovation is really one of the main
cornerstones of our neurosurgical profession. But innovation
requires an expanding talent pool and a commitment to include
the best and brightest from all aspects of society if we are to set the
pace of future discoveries.
Even as we celebrate the 30th anniversary of women in neurosurgery and nearly a century of female neurosurgeons, we know
that our journey has only just begun.
But we have great examples from history as to how to proceed. I
believe that it all starts with mentorship, as so eloquently stated by
Osler a century ago when he noted that the successful teacher is no
longer on a height, pumping knowledge into passive receptacles,
but rather together on equal footing, making the student feel that
he or she has joined a family whose interests are the mentor’s ﬁrst
consideration.
My most esteemed colleagues, the future is now. But it will
require all of us to prioritize the emerging promise of precision
medicine, and minimally invasive technology, and machine
learning and big data, to develop cures and treatments beyond our
current capabilities. As we pivot to the future, these new skills
should be placed on equal footing with traditional bedrock
principles of anatomy, neurophysiology, surgical technique, and
the patient history and physical examination. We have to do this
now. Why? Because the trajectory of our digital, device, molecular
genetic, and technological moonshot is about to become vertical. I
believe that we can accomplish all this and more by reimagining
what I call the 3 axes of neurosurgery.
The ﬁrst is redeﬁning all the skills needed to perform well in the
profession itself. Understanding that, despite our small size,
neurosurgery is the tip of the spear. Our ability to unlock the
secrets of one of the last remaining black boxes in medicine—the
wonders of the brain and all of neuroscience—will have an
outsized impact on the future of health care globally. Second, we
must seek out, and hone, those personality traits most likely to
predict success for future generations of neurosurgeons. I submit
that those who embrace innovation and who are willing to jump
right into the arena, as Teddy Roosevelt stated, with great devotion for a worthy cause and not fearing failure, are the rightful
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heirs of all those who worked tirelessly over the past century to
make ours the greatest profession imaginable. Finally, we must
refresh our educational paradigm. Abraham Flexner established a
model in 1910 that successfully improved the quality of medical
training, allowing medicine to grow into the most respected
profession, by increasing prerequisites to enter medical school,
limiting the number of medical schools to those practicing in a
scientiﬁc manner with engaged faculty in research, and strengthening state license regulations. While these core tenets rightfully
endure today, we have newer imperatives too.
Henry Ford, perhaps one of the greatest of all innovators,
intimated that we have the power within each of us to effect
change. In Flexner and Cushing’s day, the focus on quality control
for basic survival transitioned us from homeopathic remedies to a
modern age of scientiﬁc rigor. Now, well into the space age, we
need to aim for restoration of neurological function and molecular
cures by embracing the information age. While Flexner paved the
way for biological breakthroughs, we now can translate more and
more of those into actual clinical beneﬁts—from rescue to restoration and transforming lethal into chronic disease.
A century ago, Rockefeller gave $100M to revolutionize health
care. As we enhance neurosurgical education as a model for all of
medicine, our contributions should imbue new core elements into
training. First, we need to teach data science, statistical analytics,
and machine learning skills—not just facts. We need to highlight
the intricacies of healthcare policy and ﬁnances to better equip
leaders of the future, and we should consider rotations at places
such as Google, Apple, and innovation laboratories around the
world, making room for new content in our ever-changing world.
We need to nurture teachers who teach and foster team building
and communication skills with more leadership courses like the 1
pictured here. My own residents, including now 4 women in our
program who are taking neurosurgery by storm, continue to
inspire and teach me every single day.
For our generation of neurosurgeons, our time is now. Although the journey is long, what we do today will set the course
for generations to come. Of course, it is hard. But it is not like
amazing transformations that have not happened before. Because
I am from Detroit, I like to retell the story of when Henry Ford
was asked about innovation, he said that if he had just asked
people what was easiest to imagine next, they would have wanted a
faster horse. In 1900, this image of ﬁfth Avenue shows just 1
automobile amid hundreds of horse-drawn carriages. In a little
over a decade, cars became the norm, and the world was forever
transformed. Data are the currency powering our future much like
oil did in the past century. Think what neurosurgery can do now,
with our arsenal of space age tools at our ﬁngertips.
If we act today, our vision will become a reality. On this
journey, I am forever indebted to, and inspired by, my mentors
at Harvard and Henry Ford, and my neurosurgery family around
the world.
My journey simply would not have been possible without the
unconditional love and support of my own family, and they are
my greatest blessing. I have had many titles in my career, but the

neurosurgery-online.com

© Congress of Neurological Surgeons 2022. Unauthorized reproduction of this article is prohibited.

CNS PRESIDENTIAL ADDRESS 2021

ones that I value most are dad, husband, and son. To Nicholas,
Connor, and Grace, I am incredibly proud of you and all you have
accomplished in your young lives so far, and you give me the
greatest hope that our future is indeed in phenomenal hands. To
my amazing mother Grace, I will always be grateful for your
incredible sacriﬁces so that I could pursue my dreams. To Laurel,
who ﬁrst captured my heart at the age of 14 and now after 23 years
of marriage, you are the love of my life and the heart and soul of
our family.
To my colleagues, thank you for this incredible honor to serve
our profession. I know that together, we truly can shape our vision
for the future. As we contemplate these next steps in the incredible
journey of neurosurgery, my wish for all of us and our profession is
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that the future of neurosurgery is As wise as it is smart, As restless as
it is proud, As bold as it is thoughtful, As new as it is old…
In the service of our patients, as good as it is great. Thank you.
Watch Dr Kalkanis’ full Presidential Address on the Congress
of Neurological Surgeons YouTube channel at http://youtu.be/
KvPv6NO1T4c.
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